Nova Eye Medical (EYE) Discussion, page-2458

I'm confident when further growth is demonstrated heads will turn and the ridiculously low PS ratio will be noticed. Unfortunately I expect there will be some resistance to an initial share price rerate as profits are taken from the CR. If the additional sales force can come up to speed quickly and start talking to doctors, the distinct advantages of iTrack Advance should close many deals. Would love to see a March sales update with a number around $1.2 million+ US but am in no rush and expect things to look good by August EOFY. Along the way would love to hear something about China's consideration of the new product and of course 2RT but strong US sales figures around glaucoma is the key for the near term.